{"id":"NCT01435928","sponsor":"Sumitomo Pharma America, Inc.","briefTitle":"PEARL Schizophrenia Maintenance","officialTitle":"A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study Of Lurasidone For The Maintenance Treatment Of Subjects With Schizophrenia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-09","primaryCompletion":"2013-08","completion":"2013-08","firstPosted":"2011-09-19","resultsPosted":"2014-09-25","lastUpdate":"2016-04-08"},"enrollment":676,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"Lurasidone","otherNames":["Latuda"]},{"type":"DRUG","name":"Matching Placebo","otherNames":[]}],"arms":[{"label":"Lurasidone","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Lurasidone HCI is a compound that is FDA-approved for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that Lurasidone is effective in the long term maintenance treatment of schizophrenia.","primaryOutcome":{"measure":"Time to First Relapse Event During Double-blind Phase","timeFrame":"Double-blind phase - 28 Weeks","effectByArm":[{"arm":"Lurasidone","deltaMin":null,"sd":null},{"arm":"Placebo","deltaMin":192,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.039"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":75,"countries":["United States","France","Italy","Russia","Serbia","Slovakia","South Africa"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":59,"n":676},"commonTop":["Akathisia","Headache","Insomnia","Nausea","Anxiety"]}}